Document Type
Article
Publication Date
9-1-2018
Abstract
Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed utilizing modified Listeria as a tool for generating immune responses against a variety of cancers. Moreover, over a dozen clinical trials testing Listeria cancer vaccines are currently underway, which will help to understand the utility of Listeria vaccines in cancer immunotherapy. This review aims to summarize current views on how Listeria-based vaccines induce potent antitumor immunity and the current state of Listeria-based cancer vaccines in clinical trials. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
Recommended Citation
Flickinger, John C.; Rodeck, Ulrich; and Snook, Adam E., "Listeria monocytogenes as a vector for cancer immunotherapy: Current understanding and progress" (2018). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 96.
https://jdc.jefferson.edu/petfp/96
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
30044426
Language
English
Comments
This article has been peer reviewed. It is the author’s final published version in Vaccines, Volume 6, Issue 3, September 2018, Article number 48.
The published version is available at https://doi.org/10.3390/vaccines6030048. Copyright © Flickinger et al.